fig7
From: Unveiling MAGEA3: a novel predictive biomarker for bevacizumab resistance in colorectal cancer
Figure 7. Validation of prognostic effect of MAGEA3 in CRC with bevacizumab treatment. (A) Representative immunohistochemistry staining (IHC) images of MAGEA3 in CRC slices with low MAGEA3 levels and high MAGEA3 levels (scale bar: 100 μm); (B) Kaplan-Meier survival analysis of progression-free survival (PFS) between CRC patients with high or low IHC scores of MAGEA3 (P = 0.019); (C) Cox multivariate analysis of PFS in the clinical cohort shown in Figure 7B. IHC: immunohistochemistry staining; PFS: progression-free survival; CI: confidence interval.
